XCL2: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of XCL2. The page also collects GeneMedi's different modalities and formats products for XCL2 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the XCL2 target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Secreted Protein/Potential Cytokines.

Predicted to enable CCR chemokine receptor binding activity and chemokine activity. Predicted to be involved in several processes, including cellular response to cytokine stimulus; leukocyte chemotaxis; and positive regulation of T cell chemotaxis. Predicted to be located in extracellular region. Predicted to be active in extracellular space. [provided by Alliance of Genome Resources, Apr 2022]

Target IDGM-SE1387
Target NameXCL2
Gene ID6846
Gene Symbol and SynonymsSCM-1b,SCM1B,SCYC2,XCL2
Uniprot AccessionQ9UBD3
Uniprot Entry NameXCL2_HUMAN
Protein Sub-locationSecreted Protein/Potential Cytokines
Category
DiseaseN/A
Gene EnsemblENSG00000143185
Target ClassificationN/A


Pre-made anti-XCL2 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-XCL2 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-XCL2 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Antibody NameSpeciesFormatClassified by tagDetail
Anti-XCL2 monoclonal antibodyHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquinemabFACS/Biofunctional AntibodyDetail



Recombinant multi-species XCL2/ SCM-1b/ SCM1B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine XCL2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.

Products NameSpeciesExpression PlatformDetail
XCL2 proteinHuman, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, EquineMammalian cellDetail






GENEMEDI
Email: [email protected]   [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
<